A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Overview of attention for article published in Journal of Neurodevelopmental Disorders, August 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 513)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 20 news outlets
blogs: 1 blog
twitter: 10 X users

patent: 5 patents
facebook: 1 Facebook page

Citations

dimensions_citation: 69 Dimensions

Readers on

mendeley: 167 Mendeley

Summary News Blogs X Patents Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Australian Nurses Cannabis Support & Information Network, 23 Aug 2019

Clinical Trial: CBD Gel Mitigates Symptoms in Patients with Fragile X…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.